NCT00548717View on ClinicalTrials.gov

Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Graft-vs-Host Disease
Interventions
DRUG

Sirolimus

DRUG

Mycophenolate mofetil

DRUG

Bortezomib

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

PDL BioPharma, Inc.
All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

collaborator

PDL BioPharma, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT00548717 - Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter